Romidepsin: A guide to its clinical use in cutaneous T-cell lymphoma

American Journal of Clinical Dermatology

Volumn 13, Issue 1, 2012, Pages 67-71

  Lyseng Williamson, Katherine A ^a   Yang, Lily P H ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; GLYCOPROTEIN P INHIBITOR; ROMIDEPSIN; WARFARIN;

AGEUSIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; GRANULOCYTOPENIA; HEADACHE; HUMAN; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MULTIPLE CYCLE TREATMENT; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SEPSIS; THROMBOCYTOPENIA; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; DEPSIPEPTIDES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS;

EID: 84055193718     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11208520-000000000-00000     Document Type: Article

References (19)

1. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas (version 4.2011). Fort Washington (PA): National Comprehensive Cancer Network, Inc., 2011 Aug 24
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review 1975-2008. Bethesda (MD): National Cancer Institute, 2011 Apr 15
3. Whittaker SJ, Marsken JR, Spittle M, et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003 Dec; 149 (6): 1095-107 (Pubitemid 38058085)
4. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007 Sep 15; 110 (6): 1713-22 (Pubitemid 47443880)
5. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70 (3): 273-86
6. Rahman F, Robey RW, Bates SE, et al. Histone deacetylase inhibitors in oncology. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2011: 442-58
7. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009 Nov 10; 27 (32): 5459-68
8. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009 Jun 15; 15 (12): 3918-26
9. Istodax® (romidepsin) for injection: US prescribing information. Summit (NJ): Celgene Corporation, 2011 Jun
10. Rasheed W, Bishton M, Johnstone RW, et al. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 2008 Mar; 8 (3): 413-32 (Pubitemid 351836289)
11. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006 Sep; 5 (9): 769-84 (Pubitemid 44348499)
12. Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007 May; 8 (4): 383-93
13. Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010 Mar; 6 (3): 238-43
14. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010 Oct 10; 28 (29): 4485-91
15. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009 Nov 10; 27 (32): 5410-7
16. Kim E, Rook A, Kim Y, et al. Romidepsin activity in all three disease compartments (skin, blood, lymph nodes) in patients with cutaneous T-cell lymphoma (CTCL) [abstract no. 8047]. J Clin Oncol 2010 May 20; 28 (15 Suppl.)
17. Whittaker S, Kim EJ, Prince M, et al. Characterization of cyclic hematologic changes observed in patients with cutaneous T-cell lymphoma (CTCL) receiving romidepsin, a novel histone deacetylase (HDAC) inhibitor [abstract no. 3701]. Blood 2009 Nov 20; 114 (22)
18. Cabell C, Bates S, Piekarz R, et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin [abstract no. e19533]. J Clin Oncol 2009 May 20; 27 (15 Suppl.)
19. Yang LPH. Romidepsin in the treatment of T-cell lymphoma. Drugs 2011; 71 (11): 1469-80